Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 03, 2016 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 25,000 | $7.25 | 558,453 | |
| Sep 06, 2016 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 25,000 | $7.00 | 583,453 | |
| Aug 04, 2016 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 25,000 | $7.00 | 608,453 | |
| Jun 15, 2016 | Chief Operating Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 52,950 | |
| Jun 15, 2016 | General Counsel & Corp. Secy | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 | |
| Jan 04, 2016 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 28,187 | |
| Jan 04, 2016 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | -- | |
| Jan 04, 2016 | Vice President Finance | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 30,688 | |
| Jan 04, 2016 | Vice President Finance | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | -- | |
| Dec 03, 2015 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 40,687 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.